Table 2.
Unadjusted outcome rates for acute viral respiratory illness (AVRI) cohort by HTN medication group; values are numbers of episodes (percentages)
| Included cohort | |||||
| Outcome | No HTN meds* | Other HTN meds only | ACEi | ARB | Total included cohort |
| Inpatient stay for AVRI | 6868 (16.5) | 15 042 (17.1) | 9730 (13.0) | 8565 (11.6) | 33 337 (14.1) |
| ICU or CCU in inpatient stay for AVRI | 3176 (7.6) | 7390 (8.4) | 4686 (6.2) | 4087 (5.5) | 16 163 (6.8) |
| Acute respiratory distress in inpatient stay for AVRI | 401 (1.0) | 1053 (1.2) | 635 (0.8) | 530 (0.7) | 2218 (0.9) |
| Acute respiratory distress syndrome in inpatient stay for AVRI | 158 (0.4) | 349 (0.4) | 222 (0.3) | 161 (0.2) | 732 (0.3) |
| Died same or next calendar month | 2604 (6.2) | 5296 (6.0) | 2591 (3.5) | 2128 (2.9) | 10 015 (4.2) |
| N | 41 737 | 87 853 | 75 125 | 73 865 | 236 843 |
| N with consistent mortality information† | 41 682 | 87 689 | 75 009 | 73 735 | 236 433 |
*This group is not included in analyses; characteristics are presented for context.
†Denominator for death outcome excludes 410 people with inconsistent mortality information (date of death more than 1 calendar month before AVRI episode ends).
ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; CCU, coronary care unit; HTN, hypertension; ICU, intensive care unit.